TRML
Tourmaline Bio Inc

504
Mkt Cap
$1.23B
Volume
783,730.00
52W High
$48.27
52W Low
$11.56
PE Ratio
-13.97
TRML Fundamentals
Price
$47.98
Prev Close
$47.98
Open
$47.98
50D MA
$47.95
Beta
0.91
Avg. Volume
0.00
EPS (Annual)
-$2.89
P/B
4.76
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of...
PR Newswire·2mo ago
News Placeholder
More News
News Placeholder
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
Zacks·2mo ago
News Placeholder
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
Zacks·3mo ago
News Placeholder
Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened
Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price.
Stocktwits·3mo ago
News Placeholder
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·4mo ago

Latest TRML News

View

Advertisement|Remove ads.

Advertisement|Remove ads.